Mr. Rindell has more than 25 years of senior executive experience in the life sciences industry. He has held executive roles in global corporate development, business development and device/technology strategy for pharmaceutical and medical device companies in the US and Europe. Mr. Rindell has most recently served as Senior Director of Corporate Development at Amylin Pharmaceuticals, and has led key global transactions with partners including Shionogi Pharmaceuticals, BIOCON, Takeda Pharmaceuticals and device delivery companies. He also provided senior management leadership to the Amylin Drug Delivery/Device Team. He is a member of the Board of Directors of TearLab (NASDAQ: TEAR), and is an advisor to other medical device companies. He has held senior executive positions at MDG, CardioNet, Advanced Tissues Sciences, Braun/Thermoscan, and Hybritech. Mr. Rindell received his B.A. degree in Economics from the College of Wooster and an M.B.A. from Pepperdine University Graduate School of Business.